H.C. Wainwright analyst Robert Burns has reiterated their bullish stance on PMVP stock, giving a Buy rating on October 27.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Robert Burns has given his Buy rating due to a combination of factors including PMV Pharmaceuticals’ financial performance and strategic outlook. The company’s reported financials for the third quarter of 2025 showed a net loss per share that was closely aligned with expectations, indicating a stable financial position. Additionally, PMV Pharmaceuticals has a substantial cash reserve, which is anticipated to support its operations through the first quarter of 2027.
Furthermore, the valuation of PMV shares is supported by a discounted cash flow approach, factoring in a potential market value of $263 million. This valuation considers a 10% probability of approval for rezatapopt in certain solid tumors, alongside a calculated discount and terminal growth rate. However, the rating also acknowledges potential risks, such as clinical setbacks and approval challenges, which investors should consider. Overall, these elements contribute to the Buy rating, reflecting confidence in the company’s future performance and growth potential.
Burns covers the Healthcare sector, focusing on stocks such as Replimune Group, Cullinan Management, and Bicara Therapeutics Inc.. According to TipRanks, Burns has an average return of -2.6% and a 41.25% success rate on recommended stocks.
In another report released on October 27, Oppenheimer also maintained a Buy rating on the stock with a $6.00 price target.